Arix Bioscience Equity 2024

Arix Bioscience Aktienanalyse

What does Arix Bioscience do?

Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Arix Bioscience's Equity

Arix Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Arix Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Arix Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Arix Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Arix Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Arix Bioscience stock

What is the equity of Arix Bioscience this year?

Arix Bioscience has equity of 225.91 M GBP this year.

What was the equity of Arix Bioscience compared to the previous year?

The equity of Arix Bioscience has increased/decreased by -11.55% decreased compared to the previous year.

What impact does a high equity have on investors of Arix Bioscience?

A high equity is advantageous for investors of Arix Bioscience as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Arix Bioscience?

A low equity can be a risk for investors of Arix Bioscience, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Arix Bioscience affect the company?

An increase in equity of Arix Bioscience can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Arix Bioscience affect the company?

A reduction in equity of Arix Bioscience can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Arix Bioscience?

Some factors that can affect the equity of Arix Bioscience include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Arix Bioscience so important for investors?

The equity of Arix Bioscience is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Arix Bioscience take to change the equity?

To change equity, Arix Bioscience can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Arix Bioscience pay?

Over the past 12 months, Arix Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arix Bioscience is expected to pay a dividend of 0 GBP.

What is the dividend yield of Arix Bioscience?

The current dividend yield of Arix Bioscience is .

When does Arix Bioscience pay dividends?

Arix Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arix Bioscience?

Arix Bioscience paid dividends every year for the past 0 years.

What is the dividend of Arix Bioscience?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arix Bioscience located?

Arix Bioscience is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Arix Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arix Bioscience from 10/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/19/2024.

When did Arix Bioscience pay the last dividend?

The last dividend was paid out on 10/19/2024.

What was the dividend of Arix Bioscience in the year 2023?

In the year 2023, Arix Bioscience distributed 0 GBP as dividends.

In which currency does Arix Bioscience pay out the dividend?

The dividends of Arix Bioscience are distributed in GBP.